Adaptive Biotechnologies

Coming soon: T-Detect™ COVID

T-Detect is the first test resulting from Adaptive's collaboration with Microsoft. Learn more here >

Coming soon:
T-Detect™ COVID

The T-Detect™ COVID Test will be the first T-cell based clinical test that can confirm past infections with SARS-CoV-2.

Click on the link below and sign up to receive updates on test availability:

T Cells: Evolved to Detect

Learn more

Read our press release

clonoSEQ® is now FDA-cleared
for MRD assessment in patients with Chronic Lymphocytic Leukemia (CLL).

clonoSEQ® is available as a FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) , and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-regulated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.